REGENXBIO Q3 2023 Earnings Report $8.32 -0.15 (-1.77%) (As of 12:03 PM ET) Earnings HistoryForecast REGENXBIO EPS ResultsActual EPS-$1.41Consensus EPS -$1.44Beat/MissBeat by +$0.03One Year Ago EPS-$1.75REGENXBIO Revenue ResultsActual Revenue$28.90 millionExpected Revenue$26.14 millionBeat/MissBeat by +$2.76 millionYoY Revenue Growth+9.10%REGENXBIO Announcement DetailsQuarterQ3 2023Date11/8/2023TimeAfter Market ClosesConference Call ResourcesConference CallConference Call TranscriptPress ReleaseRGNX Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Trump’s Sending THIS Crypto Higher on Purpose (Ad)Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW REGENXBIO Earnings HeadlinesREGENXBIO's (RGNX) "Outperform" Rating Reiterated at Royal Bank of CanadaDecember 14, 2024 | americanbankingnews.comREGENXBIO Inc. (NASDAQ:RGNX) Receives Consensus Rating of "Moderate Buy" from AnalystsDecember 12, 2024 | americanbankingnews.comURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.December 18, 2024 | Crypto Swap Profits (Ad)RBC Capital Sticks to Its Buy Rating for RegenXBio (RGNX)December 11, 2024 | markets.businessinsider.com3 Best Stocks to Buy Now, 11/21/2024, According to Top AnalystsNovember 21, 2024 | msn.comBuy Rating on RegenXBio Driven by Positive RGX-202 Trial Results and Strong Approval ProspectsNovember 21, 2024 | markets.businessinsider.comSee More REGENXBIO Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like REGENXBIO? Sign up for Earnings360's daily newsletter to receive timely earnings updates on REGENXBIO and other key companies, straight to your email. Email Address About REGENXBIOREGENXBIO (NASDAQ:RGNX), a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.View REGENXBIO ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Cintas (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
